Barclays PLC Eliem Therapeutics, Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 29,377 shares of ELYM stock, worth $120,739. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,377
Previous 29,377
-0.0%
Holding current value
$120,739
Previous $37,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ELYM
# of Institutions
67Shares Held
49.5MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.82% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2.5MShares$10.3 Million0.01% of portfolio
-
Citigroup Inc1.61MShares$6.62 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.33MShares$5.47 Million0.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...